| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
From 13 institutes, we accumulated a retrospective cohort of 654 patients. We gave up the the NF-κB/JNK immunostaining, because we could not available the antibody of NF-κB/JNK immunostaining which we planned. So we switched an idea to existence of chronic inflammation to bring about activation of NF-κB and examined a correlation of H. pylori and prognosis. With the score-matched 222 patients in 2 groups (i.e, "surgery" or "surgery + S-1"), 5-year overall survival rate was 62% and 62% in H. pylori-positive or negative patients in surgery group; while 72% and 62% in H. pylori-positive or negative patients in S-1 group. These results indicate that the point of effect of H. pylori infection in gastric cancer treatment is chemotherapy. These clinical and epidemiological data including ourselves led us to formulate the following aims to clarify the immunological mechanisms to drive better outcome in the challenging gastric cancer treatment.
|
